Skip to main content
. 2021 May 3;6(6):485–496. doi: 10.1016/j.jacbts.2021.04.004

Figure 2.

Figure 2

Mean Percent Changes in AGT Over Time in IONIS-AGT-LRx Versus Placebo in the Add-On Study

The shaded area represents the dosing window, the arrowheads show the timepoint when the dose was given, and the unshaded area shows the follow-up period. The primary endpoint was at day 57. ∗p < 0.05; ∗∗p < 0.01, ∗∗∗p < 0.001 IONIS-AGT-LRx versus placebo at the specified timepoint. Abbreviation as in Figure 1.